Related Experiment Video
Updated: Jun 1, 2026
Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala
Published on: June 29, 2022
Targeting the endocannabinoid system in the amygdala kindling model of temporal lobe epilepsy in mice
Hannes Wendt1, Jonna Soerensen, Carsten T Wotjak
1Institute of Pharmacology, Toxicology, and Pharmacy, Ludwig-Maximilians-University, Koeniginstrasse 16, Munich, Germany.
Abstract:
The endocannabinoid system can be considered as a putative target to affect ictogenesis as well as the generation of a hyperexcitable epileptic network. Therefore, we evaluated the effect of a CB1 receptor agonist (WIN55.212-2) and of an inhibitor of the enzymatic degradation of the endocannabinoid anandamide (fatty acid hydrolase inhibitor URB597) in the amygdala kindling model of temporal lobe epilepsy. Only minor effects on seizure thresholds and seizure parameters without a clear dose-dependency were observed in fully kindled mice. When evaluating the impact on kindling acquisition, WIN55.212-2 significantly delayed the progression of seizure severity. In contrast, URB597 did not affect the development of seizures in the kindling paradigm. Analysis of cell proliferation and neurogenesis during the kindling process revealed that URB597 significantly reduced the number of newborn neurons. These data give first evidence that CB1-receptor activation might render a disease-modifying approach. Future studies are necessary that further analyze the role of CB1 receptors and to confirm the efficacy of CB1-receptor agonists in other models of chronic epilepsy.
Insights
CB1 receptor activation may modify epilepsy progression by delaying seizure severity. However, inhibiting anandamide breakdown unexpectedly reduced neurogenesis in a temporal lobe epilepsy model.
Area of Science:
- Neuroscience
- Epilepsy Research
- Endocannabinoid System
Background:
- The endocannabinoid system (ECS) is a potential therapeutic target for epilepsy.
- Cannabinoid receptor 1 (CB1) activation and modulation of anandamide levels are key ECS components relevant to ictogenesis.
Purpose of the Study:
- To investigate the effects of a CB1 receptor agonist (WIN55,212-2) and a fatty acid hydrolase inhibitor (URB597) on temporal lobe epilepsy.
- To assess their impact on seizure thresholds, seizure parameters, and kindling acquisition in the amygdala kindling model.
Main Methods:
- Utilized the amygdala kindling model in mice to simulate temporal lobe epilepsy.
- Administered WIN55,212-2 (CB1 agonist) and URB597 (anandamide degradation inhibitor).
- Evaluated seizure thresholds, seizure severity, kindling acquisition, cell proliferation, and neurogenesis.
Main Results:
- WIN55,212-2 significantly delayed seizure severity progression during kindling acquisition.
- Neither drug showed significant effects on seizure thresholds or parameters in fully kindled mice.
- URB597 significantly reduced newborn neuron numbers during the kindling process, impacting neurogenesis.
Conclusions:
- CB1 receptor activation shows potential as a disease-modifying strategy in epilepsy.
- Targeting anandamide degradation with URB597 had unintended effects on neurogenesis.
- Further research is needed to explore CB1 receptor agonists for chronic epilepsy treatment.
